Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Declaration of Voting Results of the 8th Annual General Meeting of the Company With reference to the captioned matter, we would like to state that the 8th Annual General Meeting of the Company was held on 27th July, 2018 at 'Sanskruti', Alembic Corporate Conference Center, Opp. Pragati Sahakari Bank Limited, Alembic Colony, Vadodara - 390 003.... Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 8th Annual General Meeting held on 27th July, 2018 In accordance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith proceedings of the 8th Annual General Meeting of the Company held on 27th July, 2018. We request you to kindly take the same on record. Alembic Pharma Q1 net up 36% at Rs 90 cr
Drug firm Alembic Pharmaceuticals today reported a 35.69 per cent rise in its consolidated net profit to Rs 90.47 crore for the quarter ended June 3 Unaudited Financial Results For The Quarter Ended 30Th June, 2018
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter ended on 30th June, 2018. We enclose herewith the following: a) Consolidated Unaudited Financial Results for the quarter ended on 30th June, 2018.... Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of Notice of Board Meeting published in English and vernacular language (Gujarati) newspaper on 18th July, 2018 in Economic Times English and Gujarati Edition. We request you to kindly take the same on record. Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its API Facility At Karakhadi.
We are happy to inform the exchange that the Company has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for the inspection carried out by them at our API Facility at Karakhadi during the period from 14th May, 2018 to 18th May, 2018. With this, all our manufacturing facilities for international markets are FDA compliant. We request you to kindly take the same on record. Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The exchange is hereby informed that the Company will hold Post Results Conference Call on 27th July, 2018 as per the enclosed details. Kindly take the same on record. Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June, 2018
With reference to the captioned matter, the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Thursday, 26th July, 2018 and Friday, 27th July, 2018, inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June, 2018. The Unaudited Financial Results will be presented to the Board of Directors on 27th July, 2018 for their approval and will be submitted with the stock exchanges accordingly.... Alembic Pharma gets USFDA nod for Ticagrelor tablets
Alembic Pharmaceuticals has received tentative approval from the US health regulator for Ticagrelor tablets, used to reduce the rate of cardiovascula Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Ticagrelor Tablets, 90 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.